TALKDESK
25.1.2024 17:01:28 CET | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced its presence at the All4Customer event in Paris from March 26 - 28, 2024. Investment in the event is part of the company’s commitment to the French market and to driving exceptional outcomes for customers and partners across the region with the power of artificial intelligence (AI)-driven customer experience.
Simon Desvergez, enterprise solutions engineer at Talkdesk, will deliver a masterclass on supercharging contact center optimization with generative AI (GenAI) on Wednesday, March 27, 2024 at 12:00 p.m. in Masterclass 6. During the 45-minute session, industry professionals will hear examples of how GenAI has automated complex customer use cases and significantly improved the quality of self-service interactions.
The All4Customer event, which attracts approximately 15,000 attendees, is the latest example of continued commitment from Talkdesk to the French market. Over the past several months, Talkdesk has exhibited at the Customer Relationship and Marketing Meetings (CRM&M) event in Cannes to gain opportunities to meet face-to-face with local customer experience (CX) leaders and held the Talkdesk Partner Academy in Paris as an investment in its partner ecosystem.
Tiago Paiva, founder and chief executive officer at Talkdesk, commented: “France continues to be a significant business driver for the company, and we’re excited for 2024 to drive further local expansion for Talkdesk. All4Customer is an important opportunity for us to connect with local CX leaders in-person and discuss the value that deploying AI cloud technology can unlock in the contact center.”
Customers such as Quadient, a global leader in cloud-based business communication software, parcel locker solutions, and mailing systems technology based in Bagneux, France, uses Talkdesk to deliver frictionless customer interactions. Before implementing Talkdesk, 40% of Quadient’s call volume in some queues consisted of simple transactions that could be self-serviced to reserve agents’ time for more complex tasks. Quadient initially developed its self-service solutions with Talkdesk, then expanded to other Talkdesk tools, including a solution to assist with agent coaching and a voice bot. As a result, Quadient doubled its self-service capabilities, increased efficiency, and created better experiences for customers and agents.
Jackie James, director of global operations at Quadient, said: “The thing that I like about Talkdesk more than anything is that they're constantly looking for ways to improve. They’re regularly deploying features that have positive impacts on CX." As one example of this, James added: “By using a voice bot [to serve Parcel Pending], we could contain a lot of simple transactions just by walking the customer through a few steps and using some integrations with our web application. We immediately saw a 60% containment rate.”
FACYLE, a key partner of Talkdesk in the French market specializing in Consulting and CTI integration, expressed excitement about the ongoing collaboration. As a crucial launch partner, FACYLE has significantly contributed to the success of Talkdesk in France. FACYLE Chief Executive Officer Francois Breuiller highlighted the consistent investment from Talkdesk in the success of their partnership and the French market.
The Talkdesk-FACYLE partnership has led to notable achievements, including successful projects with Groupe APRIL and Groupe Monnoyeur. This success is attributed to dedication from Talkdesk in providing resources, materials, and events tailored for the French audience. These efforts have accelerated momentum, empowering enterprises to enhance customer experiences through the Talkdesk AI-powered contact center solutions.
Francois Breuiller further emphasized the positive impact of the partnership, stating: "Partnering with Talkdesk for the past two years has proven that we made the right choice for a pure CCaaS solution. We successfully implemented their solution on large customers’ projects, showcasing robustness and comprehensive feature coverage.”
The All4Customer event will take place at Paris Expo Porte de Versailles, Pavilion 4, where Talkdesk will exhibit in stand F28. For more information, visit www.all4customer-paris.com.
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125676968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom